Skip to Main Content

WASHINGTON — Biogen’s expecting to make billions from its newly approved Alzheimer’s drug Aduhelm. But it won’t be the only one making money: the complex brain scans that help doctors decide whether a patient is a good fit for the pricey therapy will also bring in money for PET scan manufacturers and imaging drug makers, too.

If the use of those scans skyrockets, it’ll open up a new market for the companies that make the machines and the drug companies that manufacture the imaging drugs needed for those screenings.


Already, the companies behind those scans are pushing policymakers in Washington to help them make the most of the opportunity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.